Related Experiment Video

Updated: Sep 28, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Anthrax, MEK and cancer

J F Bodart1, A Chopra, X Liang

  • 1Laboratory of Developmental Cell Biology, Van Andel Research Institute, Grand Rapids, Michigan 49503 USA.

Cell Cycle (Georgetown, Tex.)
|November 14, 2002
PubMed

Insights

Anthrax lethal factor inactivates MEK signaling pathways crucial for cell growth and stress responses. This discovery opens avenues for using anthrax toxin to treat cancers driven by MEK activation.

Area of Science:

  • Molecular Biology
  • Cellular Signaling
  • Pathogenesis

Background:

  • Mitogen-activated protein kinase (MEK) kinases regulate cellular responses to mitogens and stress.
  • Aberrant MEK activation is implicated in the development of cancer (tumorigenesis).
  • Anthrax lethal factor (LF), a key component of anthrax toxin, selectively inhibits MEK activity.

Purpose of the Study:

  • To explore the molecular mechanisms of anthrax pathogenesis.
  • To investigate the role of MEK signaling in anthrax.
  • To propose novel therapeutic strategies for cancer using anthrax lethal toxin.

Main Methods:

  • Review of recent advances in understanding anthrax pathogenesis.
  • Analysis of MEK signaling pathways in the context of anthrax infection.
  • Exploration of potential applications of anthrax lethal toxin in oncology.

Main Results:

  • MEK signaling is a critical target in anthrax pathogenesis.
  • Anthrax lethal factor's selective inactivation of MEK provides a unique molecular insight.
  • The study highlights the potential of repurposing anthrax toxin for cancer therapy.

Conclusions:

  • Understanding MEK's role in anthrax pathogenesis is crucial.
  • Anthrax lethal factor's mechanism offers a novel approach for cancer treatment.
  • Targeting MEK signaling with anthrax toxin derivatives could be a promising anti-cancer strategy.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...